LONDON – U.K. rapid diagnostics specialist Mologic Ltd. has been acquired by a group of philanthropists led by George Soros’ Economic Development Fund and the Bill & Melinda Gates Foundation, and will be turned from a for-profit company to a social enterprise. The aim is to use the change in status to expand access to low-cost point-of-care testing for tropical diseases, including dengue, bilharzia and river blindness, as well at COVID-19. The name Mologic will be changed to Global Access Health (GAH), with the philanthropic owners saying they are to invest at least $41 million in the deal.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Astellas, Eli Lilly, Fibrogen, Hutchmed, Kintor.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alexion, BMS, Corvus, GSK, Innovent, Merck, Mesoblast, Orexo.
Following the temporary lapse in FDA inspections of manufacturing sites amid the COVID-19 pandemic, this year has already seen more class I medical device recalls issued than in all of 2020. The agency is now working to remediate the interruptions resulting from the pandemic among certain manufacturers of high-risk medical devices in reporting these recalls to the FDA.
SD Biosensor Inc. made a splash in its KOSPI board debut on July 16, raising a total ₩776.4 billion (US$679.26 million). The company will now use the funds to mass-produce and promote the company’s diagnostic machines for various indications, including COVID-19.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Dexcom, Foundation Medicine, NG Biotech.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Azova, Canon Medical, Cleerly, Core One Labs, Polarityte, SQI Diagnostics.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biomarin, Canbridge, Direct, Emmaus, Navidea, NLS, Ocugen, RDIF, Theratechnologies.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Checkmate, Constellation, Exevir, Generate, Gentibio, Forge, Halucenex, J&J, Kuros, Lexaria, Mithra, Morphosys, Pharmenable, Puma, Red Light Holland, Rubius, Sana, Xoma.
RSS
